A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study

In chronic lymphocytic leukemia (CLL) the level of minimal residual disease (MRD) after therapy is an independent predictor of outcome. Given the increasing number of new agents being explored for CLL therapy, using MRD as a surrogate could greatly reduce the time necessary to assess their efficacy....

Descripción completa

Detalles Bibliográficos
Autores principales: Rawstron, A C, Fazi, C, Agathangelidis, A, Villamor, N, Letestu, R, Nomdedeu, J, Palacio, C, Stehlikova, O, Kreuzer, K-A, Liptrot, S, O'Brien, D, de Tute, R M, Marinov, I, Hauwel, M, Spacek, M, Dobber, J, Kater, A P, Gambell, P, Soosapilla, A, Lozanski, G, Brachtl, G, Lin, K, Boysen, J, Hanson, C, Jorgensen, J L, Stetler-Stevenson, M, Yuan, C, Broome, H E, Rassenti, L, Craig, F, Delgado, J, Moreno, C, Bosch, F, Egle, A, Doubek, M, Pospisilova, S, Mulligan, S, Westerman, D, Sanders, C M, Emerson, R, Robins, H S, Kirsch, I, Shanafelt, T, Pettitt, A, Kipps, T J, Wierda, W G, Cymbalista, F, Hallek, M, Hillmen, P, Montserrat, E, Ghia, P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832072/
https://www.ncbi.nlm.nih.gov/pubmed/26639181
http://dx.doi.org/10.1038/leu.2015.313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832072/
https://www.ncbi.nlm.nih.gov/pubmed/26639181
http://dx.doi.org/10.1038/leu.2015.313

Ejemplares similares